Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Real-world data begin to emerge for the Jynneos vaccine in monkeypox outbreak 

By Brian Buntz | September 30, 2022

Vaccine

[Photo by Artem Podrez from Pexels]

Until recently, CDC had warned that it remained uncertain how effective the Jynneos vaccine from Bavarian Nordic A/S (OMX:BAVA) and the ACAM2000 vaccine from Emergent BioSolutions (NYSE:EBS) were at guarding against the current monkeypox outbreak. 

The CDC, however, has begun to release data related to the former vaccine. The agency found unvaccinated patients were approximately 14 times more likely to become infected with the virus based on early real-world effectiveness data. 

In the week of August 28, monkeypox incidence was 230 per 100,000 for unvaccinated individuals. Among those who received at least one dose of the Jynneos vaccine in the same period, 15 per 100,000 became infected. 

Although the U.S. government has made the ACAM2000 vaccine available for use against monkeypox, it remains unclear how protective it is in the current outbreak. 

Because data continue to be limited, CDC has counseled people who have received either vaccine to take other precautions to avoid infection. 

A recent research letter published in JAMA analyzes monkeypox infections after a single dose of the Jynneos vaccine in the U.S. Midwest. 

The research, which considered 7,339 individuals who had received their first dose of the Jynneos vaccine, found that 400 patients tested positive for monkeypox. Of those who tested positive, 37.8% had HIV.

Most monkeypox infections occurred within two weeks after receiving the first dose of the vaccine — likely before full immunity could develop. 

The authors also note that some of the infections “may not represent true vaccine failure because patients may have sought vaccination after realizing they were exposed.”

In some cases, the incubation period for monkeypox can be 17 days or more. However, one study found that the average incubation period was 8.5 days.  

The JAMA study’s authors also reported at least two breakthrough infections in individuals at least three weeks after a second dose.

The authors note that more data are needed to understand vaccine effectiveness against monkeypox. 


Filed Under: Infectious Disease
Tagged With: Bavarian Nordic, Emergent BioSolutions, Jynneos vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE